Relmada reports Q1 2026 net loss of $19.1M; NDV-01 Phase 2 shows 95% CR rate; cash $234M through 2029

RELMADA THERAPEUTICS, INC.

NDV-01 12-month Phase 2 in high-risk NMIBC: 95% CR at any time, 76% durable CR; BCG-unresponsive: 94% CR, 80% durable.
Cash balance $234.0M as of March 31, 2026, expected to fund operations through 2029 after $160M PIPE in March.
Net loss $19.1M ($0.22/share) vs $17.6M ($0.58) Q1 2025; R&D expense $8.1M; G&A $11.4M.
Phase 3 RESCUE registrational program on track for mid-2026; provisional patent filed April 2026 with term to 2047.
Upcoming milestones: IND filing mid-2026, initial Phase 3 data by YE 2026, Sepranolone Phase 2 in Prader-Willi mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.